Biotech in demand at a quiet fair | Financial

0
2


The AEX rose 0.2% to 607.4 points, after peaking at 610 points around four o’clock.

The AMX finished almost unchanged at 904.9 points. The price results elsewhere in Europe remained limited. The British FTSE 100 and French CAC 40 fell 0.4% and 0.1% respectively. The German DAX remained virtually unchanged.

That the increased doubts about AstraZeneca’s corona vaccine hardly scare investors, is not surprising analyst Jos Versteeg of InsingerGilissen. “These are preliminary research results and there may still be major changes. And the effectiveness of an average of 70% is clearly lower than with the vaccines from Pfizer and Moderna, but still positive. I therefore assume that the vaccine from AstraZeneca, which is much cheaper at a few euros per dose, will also be approved. ”

He’s especially looking forward to the Black Friday and Cyber ​​Monday sales. “Sales by brick-and-mortar stores will drop sharply, but I expect record online sales.”

Investment strategist Simon Wiersma of ING is a bit more cautious. “We are now waiting for how Black Friday sales will turn out in the US and Europe. The big question is whether the bait was good enough for bargain hunters. ”

Versteeg is concerned about a possible further increase in the number of new corona infections in the US. “If this gets out of hand, the land could be locked again. This can cause a panic reaction on the stock market. ”

On the stock exchanges, the so-called sector rotation from tech funds to financials and energy stocks has temporarily come to a standstill, Wiersma observes. “Tech funds performed well yesterday and today, while financials and energy are under pressure.”

Prosus and Galapagos in the lead

Biotechnology group ended in the AEX Galapagos with a profit of 3.7% in the lead.

Prosus gained 1.8%. The tech investor reported positive quarterly figures this week. Payment processor Adyen climbed 1.5%.

Unibail-Rodamco-Westfield plus 09%. The retail property fund has raised € 2 billion with the placement of two bonds.

The financial values ASR in ABN Amro ended with minuses of 1.5% and 1.4% at the bottom respectively.

Unilever lost 0.1%. The food group announced the acquisition of an American manufacturer of vitamins, minerals and nutritional supplements.

In the AMX shot Pharming 17.4% up. The biotechnology company has taken a concrete step towards a corridor to the Nasdaq.

Sportschoolketen Basic-Fit fell 5.6% for no concrete reason. PostNL lost 2.7%. Analysts at the German investment bank Berenberg reduced the recommendation for the mail and parcel deliverers to ‘keep’. They did increase their target price from € 2.50 to € 3.

Smallcap Neways went down 2.9%. The electronics supplier is going to cut around 250 jobs due to decreased demand from the automotive sector. A one-off provision is formed for the job losses, as a result of which Neways forecasts a negative annual result.

Ajax headed 0.5% stock. The team from Amsterdam secured wintering in European club football on Wednesday-evening thanks to a 3-1 victory over the Danish Midtjylland. A setback for Ajax, however, was that rival Atalanta Bergamo unexpectedly won at Liverpool. As a result, Ajax, Atalanta and Liverpool are now competing for two places in the sequel of the lucrative Champions League.

Vivoryon (-0.3%), which is working on an Alzheimer’s drug, suffered a loss of € 4.6 million in the third quarter. Against the rising operating and research costs, there is still no turnover.

Would you like to receive the DFT Newsletter automatically by email every morning? Sign up here for free.

LEAVE A REPLY

Please enter your comment!
Please enter your name here